Abiopharma

🔍 ONeill Francis James (Executive)

Company: Accelerant Holdings (ARX)

Report Date: 2026-07-27

Detailed Transactions and Holdings:

• Sold 110,467 shares of Class A Common Shares at $14.6308 per share (Direct)
  Date: 2026-07-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 6,626,772.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 104,647 shares of Class A Common Shares at $14.558 per share (Direct)
  Date: 2026-07-28 | Code: S | equity_swap_involved: 0 | shares_owned_after: 6,522,125.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Holds 0 shares of Class A Common Shares (Direct)
  Date: 2026-07-27 | Code: H | shares_owned_after: 166,644.00

Footnotes:

• F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2026.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.38 to $14.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.15 to $14.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.